Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.
Recent Posts
Categories
Related Articles
How many patients are switching to biosimilars?
That is a key question if long-run drug prices are going to...
Social Health Platform Pyx Health Unveils Condition Management Program
Pyx Health’s new condition management program will support people with conditions like...
Un guide sur les symptômes et la prévention des accidents vasculaires cérébraux
Un accident vasculaire cérébral survient lorsque le flux sanguin vers une partie...
Kris Engskov, Rippl
Kris Engskov is CEO of Rippl, a General Catalyst-funded company developing a...
Leave a comment